Apollomics

Apollomics (NASDAQ:APLM) has announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as changes to its executive leadership team. As a result of the updated strategic focus, and aligned with the Co.’s resource needs going forward, Sanjeev Redkar,Continue Reading